nivolumab
bms
['nadim ii', 'nadim', 'nsclc', 'congrat', 'sclc']
nadim ii trial: supports the role of neoadj chemo-io in pot resectable stage iii nsclc vs chemo; pcr (36.8% vs 6.9%), mpr (52.6% vs 13.8%) and orr (75.4% vs 48.2%). congratulations investigators! #asco22 
MD, PhD - Asst Prof, Thoracic Oncology & Precision Medicine Unit Coordinator (CEMIC). Co-Founder PxMedica: https://t.co/6HpAi0RR9P